Adenomyoepithelial tumours and myoepithelial carcinomas of the breast – a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells

Hungermann, D.; Buerger, Horst; Oehlschlegel, Christian; Herbst, Hermann; Boecker, Werner

doi:10.1186/1471-2407-5-92

Cited by 47 publications

(48 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although both subtypes clearly shared the major features of the basal cytokeratin -positive tumors (hormone receptor negativity and high tumor grade), the basal tumors were more often positive for vimentin and c-kit, which suggests that the uniformly CK5/14-positive basal tumors represent an entity that more closely resembles the primitive breast epithelium progenitor cell (14,16,19,31,32). The basoluminal tumors may represent an entity that is intermediate between uniformly CK5/14-positive basal tumors and totally CK5/14-negative luminal tumors.…”

Section: Discussionmentioning

confidence: 99%

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

Laakso

Tanner

Nilsson³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that is typically hormone receptor negative and shows a distinct gene expression profile. Based on variable basal cytokeratin immunostaining patterns, we hypothesized that the ''basal phenotype'' tumor group may comprise more than one biological entity. Experimental Design: Basal cytokeratins 5 and 14 (CK5/14) were stained by immunohistochemistry and the percentage of positive cells was defined by image analysis. The results thus obtained were compared with clinicopathologic characteristics and relapse-free survival. Results: Of the 506 breast tumors, 53 (10.5%) showed immunoreactivity for CK5/14. Basal cytokeratin expression showed up as two microscopically distinguishable subtypes, i.e., a uniformly positive type (''basal'') and a partially positive type (''basoluminal'') often displaying a checkerboard-type intratumoral heterogeneity. These subgroups could also be separated with a third basal cytokeratin (CK17, P < 0.0001). Both basal and basoluminal subtypes were hormone receptor negative and of high grade, but differed with respect to the Ki-67 labeling index (P = 0.0014), vimentin (P = 0.005), and c-kit (P = 0.02), which were more frequently expressed in basal than in basoluminal tumors. In contrast, the amplification of HER-2 was found almost exclusively in the basoluminal subgroup (P = 0.009). Compared with the basal tumors, basoluminal tumors associated with significantly shorter relapse-free survival (P = 0.01), which was not explained by their more frequent HER-2 amplification. Conclusions: We conclude that the intratumoral heterogeneity in basal cytokeratin expression can be used to define two distinct breast cancer subtypes, basal and basoluminal, with distinctive features related to proliferation activity, oncogene and biomarker status, and patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

Laakso

Tanner

Nilsson³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Vimentin expression was previously related with some breast carcinomas that today could have been included in the myoepithelial group, 33,35 whereas the remaining breast carcinomas rarely express vimentin. 33 Indeed, these tumors can be related to a previously described variety of mammary neoplasms with frequent vascular dissemination, characterized by central acellular areas and expression of cytokeratin 14 and S-100.…”

Section: Heterogeneity In Basal Breast Carcinomas E Lerma Et Almentioning

confidence: 98%

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

et al. 2007

View full text Add to dashboard Cite

Basal breast carcinomas triple negative for estrogen receptors, progesterone receptors and Her2/neu breast carcinomas are more aggressive than conventional neoplasms. We studied 64 cases with immunohistochemistry, using 23 antibodies, to characterize diverse pathological pathways. A basal cytokeratin was identified in 81% of tumors and vimentin was identified in 55%. The mean Ki67 index was 46% (range, 10-90%). Coincident expression of p50 and p65, which suggests an active nuclear factor-jB factor, was present in 13% of neoplasms. Epithelial growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGF-IR) or c-kit (CD117) was identified in 77% of tumors. Loss of protein tyrosine phosphatase was found in 14%, whereas Akt activation was present in 28%. Several differences were identified between two subtypes of basal breast carcinomas: the pure variant (negative S-100 and actin) was more frequently associated with 'in situ carcinoma' (P ¼ 0.019) and pBad overexpression (P ¼ 0.098), whereas the myoepithelial variant (positive S-100 or actin) showed more frequent tumor necrosis (P ¼ 0.048), vimentin expression (P ¼ 0.0001), CD117 expression (P ¼ 0.001) and activated caspase-3 (P ¼ 0.089). IGF-IR could be as important as EGFR for the growth of these neoplasms. Basal cell carcinoma has at least two subtypes with distinct microscopic and immunohistochemical features.

show abstract

“…Breast sarcomas have highly pleomorphic nuclei, abundant mitotic figures, and positive with CD10 and Vimentin, and negative with CD34. Myoepithelial carcinomas have an infiltrative growth pattern with biphasic or glandular pattern, are highly pleomorphic, mitotically active, and positive for Vimentin, SMA, S100, p63 and CK14 (1,10). In the present case, tumor composed of minimal atypical spindle cells surrounded open ducts and tubules without a leaf-like growth pattern.…”

Section: Discussionmentioning

confidence: 75%

Periductal Stromal Tumor of the Breast: A Case Report and Review of the Literature

Askan

Arıbal

et al. 2016

J Breasth Health

View full text Add to dashboard Cite

We present a woman aged 50 years who underwent a Tru-cut biopsy for a BI-RADS 4 lesion on her right breast and received a histopathology diagnosis of a fibroadenoma. In her one year follow-up, the lesion had progressed and she underwent an excisional biopsy. Her final diagnosis was a periductal stromal tumor. Periductal stromal tumor is an extremely rare and different entity from phylloides tumor, which makes appropriate diagnosis difficult in Tru-cut biopsy and care should be taken. Lesion progression of should require a re-biopsy. Their tendency to recur warrants follow-up. We believe that radiologic, pathologic, and clinical correlation is key in decision-making and diagnosis of these tumors.

show abstract

Adenomyoepithelial tumours and myoepithelial carcinomas of the breast – a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells

Cited by 47 publications

References 23 publications

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

Periductal Stromal Tumor of the Breast: A Case Report and Review of the Literature

Contact Info

Product

Resources

About